Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002117 | 1.00 | CA12 (0.42) | CA12CA14APLNRDGAT1CA2 | |
| SCHEMBL3008075 | 1.00 | CA12 (0.42) | CA12CA14APLNRDGAT1CA2 | |
| Hydrochloric Acid SCHEMBL3014916 | 0.98 | CA12 (0.41) | CA12CA14APLNRDGAT1CA2 | |
| Oxalic Acid SCHEMBL16148596 | 0.95 | CA12 (0.40) | CA12CA14APLNRDGAT1CA2 | |
| Oxalic Acid SCHEMBL16148595 | 0.95 | CA12 (0.40) | CA12CA14APLNRDGAT1CA2 | |
| SCHEMBL13984531 | 0.83 | MEN1 (0.42) | CA12CA14APLNRCA2CA1 | |
| SCHEMBL21612221 | 0.83 | MEN1 (0.42) | CA12CA14APLNRCA2CA1 | |
| SCHEMBL12467107 | 0.83 | MEN1 (0.42) | CA12CA14APLNRCA2CA1 | |
| SCHEMBL16855011 | 0.80 | APLNR (0.41) | CA12CA14APLNRDGAT1CA2 | |
| SCHEMBL17035397 | 0.79 | CA12 (0.47) | CA12CA14APLNRDGAT1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827612-B2 | Hydroxamic acid derivative, method for producing same and use thereof | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-11-28 | — | — | US | claimed |
| EP-4071134-A1 | HYDROXAMIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2022-10-12 | — | — | EP | claimed |
| US-20220033369-A1 | HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME AND USE THEREOF | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-02-03 | — | — | US | claimed |
| EP-3817742-B1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | TEMMUNE THERAPEUTICS NV (BE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250082609-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Metrion Biosciences Limited (GB) | 2025-03-13 | — | — | US | disclosed |
| WO-2025031048-A1 | HYDROXAMIC ACID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF AND PREPARATION METHOD THEREFOR | 中国医学科学院医药生物技术研究所 | 2025-02-13 | — | — | WO | disclosed |
| US-20250051269-A1 | PROCESS OF THE PREPARATION OF HYDROXYLAMINE DERIVATIVES | INTERVET INC. (US) | 2025-02-13 | — | — | US | disclosed |
| US-12220461-B2 | Polypeptide-coupled small molecule compound and antiviral application thereof | GUANGZHOU MEDICAL UNIVERSITY (CN) | 2025-02-11 | — | — | US | disclosed |
| US-12195466-B2 | Polyproline mimetics of proline-derived module-15 | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2025-01-14 | — | — | US | disclosed |
| EP-4452921-A1 | PROCESS OF THE PREPARATION OF HYDROXYLAMINE DERIVATIVES | Intervet International B.V. (NL) | 2024-10-30 | — | — | EP | disclosed |
| WO-2012154204-A1 | HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | ACHAOGEN, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012031298-A2 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| CN-101765585-A | Antibacterial agent | ACHAOGEN INC | 2010-06-30 | — | — | CN | disclosed |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| WO-2010031750-A1 | ORGANIC COMPOUNDS FOR APPLICATIONS IN BACTERIAL INFECTIONS TREATMENT | NOVARTIS AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082609-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | STS, SQOR, SULT2A1 | CA12 395/4885CA14 316/4885APLNR 1886/4885 |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | CA12 4051/4885CA14 3029/4885APLNR 3978/4885 |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CA12 886/4885CA14 778/4885APLNR 3930/4885 |
| US-12220461-B2 | Polypeptide-coupled small molecule compound and antiviral application thereof | PEPD, PREP, VIP | CA12 2076/4885CA14 2318/4885APLNR 314/4885 |
| US-20220033369-A1 | HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME AND USE THEREOF | HACL2, NAAA, LCT | CA12 792/4885CA14 1025/4885APLNR 2006/4885 |
| US-12195466-B2 | Polyproline mimetics of proline-derived module-15 | PRAP1, ENPEP, RRP15 | CA12 3983/4885CA14 3931/4885APLNR 1159/4885 |
| US-20250051269-A1 | PROCESS OF THE PREPARATION OF HYDROXYLAMINE DERIVATIVES | HAAO, HNMT, ADH1A | CA12 2182/4885CA14 1546/4885APLNR 3485/4885 |
| US-11827612-B2 | Hydroxamic acid derivative, method for producing same and use thereof | HACL2, NAAA, LCT | CA12 792/4885CA14 1025/4885APLNR 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.